Healio Minute

In this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more. Read the full coverage here:

Combination extends survival vs. standard first-line therapy for advanced lung cancer

Integrated care 'best treatment option' for smoking cessation during lung cancer screening

FDA proposes cap on nicotine levels in cigarettes

Global lifetime risk for lung cancer in 2022 differs by human development index, sex

FDA grants priority review to oral non-small cell lung cancer drug

References:

Cinciripini P, et al. JAMA Intern Med. 2024;doi:10.1001/jamainternmed.2024.7288.

Li M, et al. Chin Med J (Engl). 2024;doi:10.1097/CM9.0000000000003368.

Press Release

Press Release

Press Release

In this edition, we bring you Healio's top lung cancer headlines in 2024.

Read the full coverage here:

California doctor with lung cancer receives first-of-its-kind lung-liver transplant

'We were shocked': Vaping considerably increases lung cancer risk among people who smoke

FDA places hold on trial of cell therapy for lung cancer after patient death

Findings highlight 'desperate need' to improve end-of-life cancer treatment

'We have the technology': Telehealth increases access to palliative care for cancer

References:

Canavan ME, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1129.

Greer JA, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

Healio Interviews

Press Release

Press Release

In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more. Read the full coverage here:

Single-fraction SBRT confers 'surprisingly excellent' outcomes for central lung tumors

Adjuvant durvalumab extends survival in limited-stage small cell lung cancer

Depression among people with head and neck cancers likely underreported, undertreated

FDA approves tumor treating fields as part of combination therapy for advanced lung cancer

First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer

References:

Cheng Y, et al. Abstract LBA81. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain.

Malik NK, et al. Abstract 285. Presented at: ASTRO Annual Meeting; Sept. 29-Oct. 2, 2024; Washington, D.C.

Martinez MC, et al. JAMA Otolaryngol Head Neck Surg. 2024;doi:10.1001/jamaoto.2024.3233.

Press Release

Press Release

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more. Read the full coverage here:

FDA approves Rybrevant for advanced lung cancer

Lung cancer screening orders in eligible patients higher with digital health program

FDA approves Opdivo regimen for resectable NSCLC

Study quantifies survival benefit of immunotherapy in metastatic NSCLC

FDA expands osimertinib approval for advanced non-small cell lung cancer

References:

Miller DP, et al. A direct-to-patient digital health program increases lung cancer screening: A pragmatic randomized controlled trial of mPATH-Lung. Presented at: CHEST Annual Meeting; Oct. 6-9, 2024; Boston.

Press Release

Press Release

Press Release

Ward Y, et al. Cancer. 2024;doi:10.1002/cncr.35476.

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here:

Blue-collar workers more likely to miss work, quit due to psoriatic arthritis

Infliximab biosimilar uptake rapidly increased only after release of a third option

National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala

Safety checklist compiles clinically important DMARD warnings in one place

Guselkumab demonstrates long-term efficacy, safety in psoriasis

References:

Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.

Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.

Press Release

Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.

Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab 'may be a new standard' and more. Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be 'a new standard'

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen 'merits further study' for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, Ivonescimab 'may be a new standard' and more. Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be 'a new standard'

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen 'merits further study' for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Read the full coverage here:

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema

OCS-01 eye drop for DME in second stage of phase 3 trial

Q&A: Susvimo delivers immediate durability after implantation in wet AMD

References:

Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Press Release

Press Release

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Read the full coverage here:

Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations

Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease

Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk

S100 protein levels predict abatacept response in juvenile idiopathic arthritis

Izokibep shows early promise in hidradenitis suppurativa

References:

Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.

Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.

Press Release

Press Release

Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.